At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study.
In Brief
A clinical study evaluating Nasafytol® (Quercetin/Curcumin Supplement) for Long COVID. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.
Study Details
Timeline
Interventions
Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.